Early Detection of Prostate Cancer

Launched by UNIVERSITY HOSPITAL, MONTPELLIER · Sep 18, 2020

Keywords

ClinConnect Summary

This clinical trial is focused on finding new ways to detect prostate cancer early by examining specific markers found in the blood. Researchers are particularly interested in looking for circulating tumor cells and their products, which can provide important clues about the presence of cancer. The study aims to identify the most effective blood tests for distinguishing between men with prostate cancer and those without, especially targeting those at higher risk with more aggressive forms of the disease. Over the next few years, the team will test these markers against traditional methods already approved for use.

To participate in this study, men over 40 who have either been diagnosed with prostate cancer or are suspected of having it may be eligible, especially if they have a certain level of PSA (a protein linked to prostate issues) in their blood. Participants will need to attend regular visits and undergo specific testing, including an MRI before a biopsy. Control participants—men over 40 with no suspicion of prostate cancer—will also be sought. This study is a chance to contribute to advancing prostate cancer detection methods, and all participants will be closely monitored throughout the trial.

Gender

MALE

Eligibility criteria

• Inclusion Criteria Patient :
• • Men over 40 being suspicious of prostate cancer
• • Subject with PSA ≥ 4 and designated for biopsy
• • Subjects must be able to attend all scheduled visits and to comply with all trial procedures
• • mpMRI done before prostate biopsy
• • Subject must be covered by public health insurance
• • Signed informed consent form
• Inclusion Criteria Subject Control Patient patient free from prostatic disease :
• • Men over 40 with no suspicion of prostate cancer
• • Subject with PSA \< 2.5 and normal digital rectal examination
• • Subject must be covered by public health insurance
• • Signed informed consent form
• Exclusion Criteria Patient :
• • Subject with histologically confirmed prostate cancer
• • Subject with a verified viral infection (HIV or Hepatitis)
• • Subject under Finasteride treatment
• • Subject under hormonal treatment (analogs, antagonists, androgenics)
• • Subject with other cancer diagnosed
• • Subject unable to sign consent
• • Planned longer stay outside the region that prevents compliance with the visit plan
• • Subject deprived of liberty, protected adults or vulnerable persons
• • Urinary infection ≤ 2 months
• • Subject excluding health insurance registration
• • Subject refusing to perform prostate biopsy
• • Subject who are in a dependency or employment with the sponsor or the investigator
• Exclusion Criteria Subject Control :
• • Subject with histologically confirmed prostate cancer
• • Subject with a verified viral infection (HIV or Hepatitis)
• • Subject under Finasteride treatment
• • Subject with other cancer diagnosed
• • Subject unable to sign consent
• • Planned longer stay outside the region that prevents compliance with the visit plan
• • Subject deprived of liberty, protected adults or vulnerable persons
• • Urinary infection ≤ 2 months
• • Subject excluding health insurance registration